Publications by authors named "Robert Gut"

Claim this Profile
S
Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
Annette von Drygalski, Esteban Gomez, Adam Giermasz, Giancarlo Castaman, Nigel S Key, Robert Gut

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Steven W Pipe, Frank W G Leebeek, Michael Recht, Nigel S Key, Giancarlo Castaman, Robert Gut

N Engl J Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S Key, Susan Lattimore, Robert Gut

Blood Adv· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study.
Alice D Ma, Craig M Kessler, Hamid A B Al-Mondhiry, Robert Z Gut, David L Cooper

Blood Coagul Fibrinolysis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry.
Craig M Kessler, Alice D Ma, Hamid A B Al-Mondhiry, Robert Z Gut, David L Cooper

Blood Coagul Fibrinolysis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRENDS IN GROWTH HORMONE STIMULATION TESTING AND GROWTH HORMONE DOSING IN ADULT GROWTH HORMONE DEFICIENCY PATIENTS: RESULTS FROM THE ANSWER PROGRAM.
Murray B Gordon, Richard A Levy, Robert Gut, John Germak

Endocr Pract· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.
Judith L Ross, Peter A Lee, Robert Gut, John Germak

Growth Horm IGF Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study.
Susan R Rose, Grafton Reeves, Robert Gut, John Germak

J Pediatr· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program.
Judith L Ross, Peter A Lee, Robert Gut, John Germak

Int J Pediatr Endocrinol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the Dosing Observational Study in Hemophilia (DOSE).
Michael Recht, Ellis J Neufeld, Vivek R Sharma, Caitlyn T Solem, A Simon Pickard, Robert Z Gut

Value Health· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project.
Steven R Lentz, Anand Tandra, Robert Z Gut, David L Cooper

J Blood Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia.
Ellis J Neufeld, Michael Recht, Hernan Sabio, Kapil Saxena, Caitlyn T Solem, Robert Z Gut

Value Health· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE).
Guy Young, Caitlyn T Solem, Kate Hoffman, Jenna Kabawat, A Simon Pickard, Robert Z Gut

J Blood Med· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry.
Peter A Lee, Judith Ross, John A Germak, Robert Gut

Int J Pediatr Endocrinol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of age and duration of growth hormone therapy in children with Turner syndrome.
Judith Ross, Peter A Lee, Robert Gut, John Germak

Horm Res Paediatr· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors influencing the one- and two-year growth response in children treated with growth hormone: analysis from an observational study.
Judith Ross, Peter A Lee, Robert Gut, John Germak

Int J Pediatr Endocrinol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®.
Peter A Lee, John Germak, Robert Gut, Naum Khutoryansky, Judith Ross

Int J Pediatr Endocrinol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endometrial safety of ultra-low-dose estradiol vaginal tablets.
James Simon, Lila Nachtigall, Lian G Ulrich, Michaela Eugster-Hausmann, Robert Gut

Obstet Gynecol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet.
James Simon, Lila Nachtigall, Robert Gut, Eva Lang, David F Archer

Obstet Gynecol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
Gloria Bachmann, Rogerio A Lobo, Robert Gut, Lila Nachtigall, Morris Notelovitz

Obstet Gynecol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis